Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos(University of Liverpool), Markus W. Büchler(Heidelberg University)
The Lancet
January 24, 2017
Cited by 1,919


Related Papers